Ilenia Segatto
Overview
Explore the profile of Ilenia Segatto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Segatto I, Rampioni Vinciguerra G, Pellarin I, DallAcqua A, Berton S, Citron F, et al.
Cancer Commun (Lond)
. 2023 Jun;
43(7):844-849.
PMID: 37337406
No abstract available.
12.
Rampioni Vinciguerra G, Sonego M, Segatto I, DallAcqua A, Vecchione A, Baldassarre G, et al.
Front Oncol
. 2022 Jun;
12:891580.
PMID: 35712501
The cyclin D-CDK4/6 complexes play a pivotal role in controlling the cell cycle. Deregulation in cyclin D-CDK4/6 pathway has been described in many types of cancer and it invariably leads...
13.
Rampioni Vinciguerra G, DallAcqua A, Segatto I, Mattevi M, Russo F, Favero A, et al.
Cell Death Dis
. 2021 Oct;
12(10):951.
PMID: 34654798
In colorectal cancer, mutation of KRAS (RAS) reduces therapeutic options, negatively affecting prognosis of the patients. In this setting, administration of CDK4/6-inhibitors, alone or in combination with other drugs, is...
14.
Citron F, Segatto I, Musco L, Pellarin I, Rampioni Vinciguerra G, Franchin G, et al.
EMBO Mol Med
. 2021 Jun;
13(7):e12872.
PMID: 34062049
Radiotherapy (RT) plus the anti-EGFR monoclonal antibody Cetuximab (CTX) is an effective combination therapy for a subset of head and neck squamous cell carcinoma (HNSCC) patients. However, predictive markers of...
15.
Favero A, Segatto I, Perin T, Belletti B
Wiley Interdiscip Rev RNA
. 2021 May;
12(6):e1659.
PMID: 33951281
Given their intrinsic pleiotropism, microRNAs (miR) play complex biological roles, in both normal and pathological conditions. Often the same miR can act as oncogene or oncosuppressor, depending on the biological...
16.
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra G, DallAcqua A, et al.
J Pathol
. 2020 Nov;
253(2):234-245.
PMID: 33140857
The CDKN1B gene, encoding for the CDK inhibitor p27 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from small...
17.
Ranzuglia V, Lorenzon I, Pellarin I, Sonego M, DallAcqua A, DAndrea S, et al.
Oncogene
. 2020 Aug;
39(40):6370-6386.
PMID: 32848212
For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance...
18.
Citron F, Segatto I, Rampioni Vinciguerra G, Musco L, Russo F, Mungo G, et al.
Cancer Res
. 2019 Dec;
80(5):1064-1077.
PMID: 31862778
miR-223 is an anti-inflammatory miRNA that in cancer acts either as an oncosuppressor or oncopromoter, in a context-dependent manner. In breast cancer, we demonstrated that it dampens the activation of...
19.
Rampioni Vinciguerra G, Citron F, Segatto I, Belletti B, Vecchione A, Baldassarre G
Cell Div
. 2019 Apr;
14:2.
PMID: 30976290
The p27 protein, mainly known as a negative regulator of cell proliferation, has also been involved in the control of other cellular processes, including the regulation of cytoskeleton dynamics. Notably,...
20.
Segatto I, De Marco Zompit M, Citron F, DAndrea S, Rampioni Vinciguerra G, Perin T, et al.
Cancer Res
. 2018 Nov;
79(2):397-409.
PMID: 30478213
Postnatal development of the mammary gland relies on the maintenance of oriented cell division and apicobasal polarity, both of which are often deregulated in cancer. The microtubule (MT) network contributes...